Deal dashboards
Pharmaceutical & Biotech Deals Dashboard
Comprehensive Analysis: July 28 - August 2, 2025
$15.8B+
Total Deal Value
Disclosed & Potential
23
Major Transactions
Across All Categories
$12B
Largest Deal
GSK-Hengrui Partnership
$564M
Venture Capital
Private Investment
Deal Values by Transaction Type ($M)
Top 10 Deals by Value
Weekly Deal Timeline
Monday, July 28, 2025
LICENSING
$12B
GSK & Hengrui Pharmaceuticals - 12-program strategic alliance
VENTURE
$372.5M
MapLight Therapeutics Series D - CNS therapeutics
VENTURE
$60M
VelaVigo Pre-A+ - Multi-specific antibodies
M&A
$55M
Adaptimmune sells 4 cell therapies to US WorldMeds
Tuesday, July 29, 2025
M&A
$413M
Bausch Health acquires DURECT - Liver disease therapy
VENTURE
$132M
ARTBIO Series B - Radiopharmaceuticals
Wednesday, July 30, 2025
ROYALTY
Undisclosed
KKR acquires HealthCare Royalty Partners
M&A
~$1B
AbbVie in talks to acquire Gilgamesh - Psychiatric treatments
Thursday, July 31, 2025
ROYALTY
$70M
Ligand & Medtronic invest in Orchestra BioMed
FUND
$1.3B
Frazier Life Sciences Fund XII closes
Friday, August 1, 2025
LICENSING
$354M
Novo Nordisk & Gensaic - AI-driven protein design
LICENSING
$856M
Eli Lilly & Gate Bioscience - Molecular gates platform
M&A
$130M
Sanofi acquires China rights from Arrowhead
Friday, August 2, 2025
IPO
$20M
Blue Water Vaccines NASDAQ debut - Universal flu vaccine
Investment by Therapeutic Area
Geographic Distribution of Deals
Key Insights
- East-West collaborations dominate with $13B+ in cross-border deals
- Royalty financing sector consolidates with KKR's strategic acquisition
- Venture capital focuses on next-gen platforms: radiopharmaceuticals, AI-driven design
- Public markets remain challenging with only 1 IPO during the week
- Geographic concentration in North America (52%) and Europe (26%)
- Oncology and CNS therapeutics attract highest valuations